{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DMARDs&page=2", "query": { "intervention": "DMARDs", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DMARDs&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T01:59:35.500Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06418529", "title": "A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "tofacitinib", "type": "DRUG" }, { "name": "tumor necrosis factor inhibitors (TNFi)", "type": "DRUG" }, { "name": "abatacept", "type": "DRUG" }, { "name": "tocilizumab or sarilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21340, "start_date": "2024-05-15", "completion_date": "2024-07-19", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06418529" }, { "nct_id": "NCT01307423", "title": "Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Apremilast 20mg", "type": "DRUG" }, { "name": "Apremilast 30mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 529, "start_date": "2010-12-09", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307423" }, { "nct_id": "NCT01844518", "title": "Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Active Polyarticular Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 219, "start_date": "2013-08-30", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844518" }, { "nct_id": "NCT05543642", "title": "The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatic Diseases" ], "interventions": [ { "name": "Hepatitis A vaccine", "type": "BIOLOGICAL" }, { "name": "Diphtheria, pertussis, and tetanus booster vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2022-10-11", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 7, "location_summary": "Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more", "locations": [ { "city": "Northport", "state": "Alabama" }, { "city": "Riverview", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Clovis", "state": "New Mexico" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05543642" }, { "nct_id": "NCT00396812", "title": "Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2006-11", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00396812" }, { "nct_id": "NCT01721057", "title": "A Study in Moderate to Severe Rheumatoid Arthritis Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "cDMARD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 684, "start_date": "2012-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 48, "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721057" }, { "nct_id": "NCT03414502", "title": "Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 400, "start_date": "2007-12-10", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414502" }, { "nct_id": "NCT04286789", "title": "Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Low dose ORTD-1", "type": "DRUG" }, { "name": "Low dose vehicle control", "type": "DRUG" }, { "name": "High dose ORTD-1", "type": "DRUG" }, { "name": "High dose vehicle control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oryn Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-22", "completion_date": "2021-10-12", "has_results": false, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 3, "location_summary": "Los Angeles, California • Tustin, California • Miami, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04286789" }, { "nct_id": "NCT01695239", "title": "A Study of Ixekizumab in Participants With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis, Arthritic" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 417, "start_date": "2012-12", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01695239" }, { "nct_id": "NCT00856544", "title": "A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 795, "start_date": "2009-05", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-09-04T01:59:35.500Z", "location_count": 46, "location_summary": "Huntsville, Alabama • Jonesboro, Arkansas • Palo Alto, California + 41 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856544" } ] }